Replies to post #110156 on Bagman's charts, watchlists, scans and etc.

[maybe_this_time]

Yup market of 36 million with 40 million in the bank and only burning about 3.5 million a quarter... Seems like a pretty good bet here, especially if they can get a drug approved:

ANX-188, a rheologic, antithrombotic, and cytoprotective agent, which improves microvascular blood flow and has potential application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. Its other programs comprise Exelbine or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine); and ANX-514, a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel.